2015 American Transplant Congress
Outcomes in Liver Re-Transplant Recipients With MELD above 40: A Decade Long Experience
Introduction:A significant proportion of liver transplant recipients will suffer from graft loss, after which liver retransplant (reLTx) becomes their only therapeutic option. Patients with very…2015 American Transplant Congress
Acute Kidney Injury in the MELD Era of Liver Transplantation. Are Calcineurin Inhibitors So Problematic for Renal Function?
Acute kidney injury(AKI)after liver transplantation (LT) is common.Calcineurin inhibitors(CNI)have to be well-balanced.The aims were analyze the specific effect of CNI on AKI in a cohort…2015 American Transplant Congress
Ethnic Barriers in Pediatric Liver Transplant Recipients. A Retrospective Study
INTRODUCTION: Differences in access to OLTx continue to be present in minorities. Pediatric pts represent a particularly vulnerable population within minorities groups in need for…2015 American Transplant Congress
Domino Liver Transplant from Donors With MSUD: Operative Strategy and Long-Term Outcomes
Liver transplant (txp) is the definitive branched chain keto-acid (BCKA) replacement therapy for patients with Maple Syrup Urine Disease (MSUD). Due to the extra-hepatic distribution…2015 American Transplant Congress
Galectin-9 Protects Mouse Liver Transplants Against Ischemia-Reperfusion Injury
Dept of Surgery, Dumont-UCLA Liver Transplant Center, Los Angeles, CA.
Background:Although Galecin 9 (Gal-9) negatively regulates Th1-type alloimmunity by binding to T-cell Immunoglobulin Mucin-3 (TIM-3) on activated Th1 cells, its role in liver ischemia-reperfusion injury…2015 American Transplant Congress
A Tool to Estimate Probability of Outcomes on the Liver Transplant Waiting List
The probability of liver transplant (LTX) and death for candidates varies by donation service area (DSA), making it difficult for candidates to understand the likely…2015 American Transplant Congress
The Higher MFI of De Novo Donor-Specific Anti-HLA Antibodies Is Correlated With Graft Fibrosis Progression in Living Donor Liver Transplantation
Background. It has been shown that the development of de novo donor-specific anti-HLA antibodies (DSA) is associated with poorer graft outcome in kidney transplantation. However…2015 American Transplant Congress
Interferon-Free Sofosvir/Ribavirin Treatment Achieves Excellent Sustained Viral Response in Post Liver Transplant HCV Recipients
Purpose: HCV is the leading cause of end-stage liver disease, universally recurring in the post-transplant setting. Studies have shown disappointing results after first generation protease…2015 American Transplant Congress
Basiliximab Induction With Delayed Tacrolimus Initiation up to 14 Days Post Liver Transplantation Maintains Excellent Clinical Outcomes While Preserving Renal Function
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors are frequently delayed to allow for recovery of renal function after transplantation; however, there is a paucity of literature supporting a delay…2015 American Transplant Congress
Comparison of Risk Factors and Outcomes of Daptomycin-Susceptible and -Nonsusceptible Enterococcus Infections in Liver Transplant Recipients
University of Virginia, Charlottesville, VA.
PurposeDaptomycin (DAP) has become an important therapeutic agent to treat infections due to vancomycin-resistant Enterococcus faecium (VRE), including in liver transplant recipients (LTRs); however, DAP-nonsusceptible…
- « Previous Page
- 1
- …
- 165
- 166
- 167
- 168
- 169
- …
- 180
- Next Page »